Zeria Pharmaceutical Co., Ltd.
Q1 Fiscal Year 2027 Financial Summary [Japan GAAP] (Consolidated)
Sales for the first quarter of fiscal year 2027 were 21.448 billion yen, up 10.1% YoY; operating income was 1.95 billion yen, up 28.3% YoY. Ordinary income was 1.432 billion yen, down 13.8% YoY, and net income attributable to owners of the parent was 866 million yen, down 20.6% YoY. Full-year guidance remains as announced, with effects of exchange rate losses considered; performance is expected to proceed as planned.
Key Figures
- Net sales: 214,480 million yen (YoY +10.1%)
- Operating income: 19,500 million yen (YoY +28.3%)
- Ordinary income: 14,320 million yen (YoY △13.8%)
AI要約
Summary of Results
Total net sales for the first quarter stood at 21,448 million yen, achieving growth year over year. However, ordinary income decreased due to foreign exchange losses. In the segments, the Pharmaceuticals for Medical Use segment remained solid, with progress in product penetration domestically and internationally. Consumer Healthcare contributed from sales growth of the Heparin series. Other businesses declined slightly. There is no change to the full-year outlook at this time.
Outlook and Capital Position
From the second quarter onward, performance is expected to proceed largely as planned. Considering currency fluctuations, there will be no changes to consolidated earnings projections. Total assets fluctuated, and the equity ratio improved to 61.8%. Reductions in short-term borrowings and decreases in corporate taxes contributed. No additional information on dividend outlook has been disclosed.
Zeria Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
